Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675103 · ClinicalTrials.gov registry record · Phase 3
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
A Phase 3 study, sponsored by Savient Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT00675103: Completed Phase 3 study, sponsored by Savient Pharmaceuticals.
NCT00675103 is a Phase 3 study that has completed, run by Savient Pharmaceuticals. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00675103, a Phase 3 study, has completed, sponsored by Savient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry. This study is limited to four study centers in the US.
Primary Outcome
Number of participants reporting events
Interventions
- DRUG pegloticase 8 mg i.v.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00675103 record still lists
NCT00675103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which pegloticase 8 mg i.v. is the first listed.
NCT00675103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00675103 about?
NCT00675103 is a clinical study titled "Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients". The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry. This study is limited to four study centers in the US.
What is the current status of trial NCT00675103?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2008-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00675103?
The interventions under investigation include: pegloticase 8 mg i.v. (DRUG).
Who is sponsoring clinical trial NCT00675103?
This trial is sponsored by Savient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00675103's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia